Abstract: The invention provides an Auricularia auricula polysaccharide, its application and preparation method thereof, which belong to the technical field of improving polysaccharide. After being degreased, the Auricularia auricula is subjected to preliminary enzymolysis under the effect of helicase, is further subjected to deep enzymolysis under the effect of complex enzyme through synergetic ultrasound-assisted degradation and extraction with H2O2, and is subjected to mixed fermentation by Lactobacillus bulgaricus, Streptococcus thermophilus and Bifidobacterium longum, the obtained fermented Auricularia auricula polysaccharide is subjected to a phosphorylation reaction under the effect of a phosphorylation reagent, and after further deproteinization and decolorization, the obtained fermented Auricularia auricula polysaccharide is chelated with zinc salt to obtain a polysaccharide-zinc compound, and the amount of the extracted Auricularia auricula polysaccharide is improved.

Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

Abstract: A PD-1 variant, which has improved binding affinity to PD-L1, and methods for preparing and screening the PD-1 variant. The PD-1 variant of the present disclosure effectively inhibits the binding between wild-type PD-1 and PD-L1, and thus is expected to have significantly higher penetration ability and anticancer effect by immune cells or therapeutic effect for infectious diseases as compared to existing immune checkpoint inhibitors. At the same time, the possibility of immunogenicity can be minimized. In addition, the convenience of developing biomedicine may be promoted through aglycosylation.

Abstract: A biological seed-coating agent (SCA) including a fermentation broth obtained based on co-cultivation of Trichoderma and Bacillus sequentially inoculated, and a preparation method thereof are provided. According to a principle of synthesis biology, Trichoderma that induces disease resistance and stress resistance and Bacillus that antagonizes pathogens and promotes crop growth are inoculated in stages for co-fermentation to prepare a microbial co-culture solution. The microbial co-culture solution is mixed with diatomaceous earth and brassinolide according to a specified ratio to prepare a biological SCA in a dosage form of a powder. The biological SCA includes high contents of spores and antagonistic and growth-promoting substances.

Abstract: The disclosure relates to the field of reducing malodor that is due to bacterial conversion of molecules that are present in sweat. This disclosure describes purified enzymes, lyophilized or non-living bacteria, bacterial lysates, and/or bacterial fragments that contain the functional potential to fully catabolize the human skin lipids and squalene, so no malodor arises. The disclosure also describes enzymes that produce a natural fragrance from squalene breakdown products. The compounds of the disclosure can, thus, be used in deodorants, washing powders, clothing finishing agents or in any method to reduce malodor.

Abstract: The present disclosure discloses Saccharopolyspora and application thereof in reducing biogenic amines, belonging to the technical field of food fermentation. Saccharopolyspora jiangxiensis J3 is screened from wheat koji and has been preserved in China Center for Type Culture Collection (CCTCC) on Apr. 30, 2020, with a preservation number of CCTCC NO: M 2020104. According to the present disclosure, the strain is applied to a food fermentation system, and results show that the strain does not affect normal fermentation of food, and has an effect of reducing the content of biogenic amines in fermented alcoholic drinks, fermented food and fermented condiments, so that the strain has broad application prospects in the field of food brewing.

Abstract: The present invention relates to: a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure; and a use thereof. More particularly, it was confirmed that polyethylene microspheres (PS) in a mouse animal model orally administered with the PS penetrate brain tissue to change the level of metabolites inside the brain tissue and the diversity of intestinal microorganisms, thereby causing brain disease, and thus the present invention is intended to provide a biomarker composition for predicting the prognosis of brain disease caused by microplastic exposure, and a method for predicting the prognosis of brain disease using same.

Abstract: An organic formulation based on a mixture of microorganisms and other derived organic components, obtained from plants that inhabit different extreme environments, including the Chilean Antarctic territory, for protecting plants and agricultural crops against environmental conditions, especially with respect to cold stress, water stress, and plant infection by pests and insects, is provided. Due to the activity of the consortia of microorganisms that compose it and its derived components, it favours plant growth and reduces the damage associated with cold and water stress in agricultural crops.

Abstract: The present invention relates to the strain Phascolarctobacterium faecium DSM 32890 and to its use for the regulation of appetite and the treatment and/or prevention of overweight or the associated metabolic and immunological changes, specifically, hyperglycaemia, glucose intolerance, insulin resistance, dyslipidemia (hypertriglyceridemia, hypercholesterolemia), metabolic syndrome, diabetes and intestinal and/or peripheral tissue inflammation.

Abstract: Described herein are methods for treating radicular pain due to radiculopathies comprising administering a therapeutically effective amount of a composition comprising cell-free amniotic fluid.

Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.

Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.

Abstract: An object of the present invention is to provide a composition for promoting sleep, that enables an increase of the sleep amounts in the overall night and in the initial stage of the night, a decrease of the sleep onset latent time, and an increase of the length of a sleep episode, and that is excellent in the stability and the safety. Another object of the present invention is to provide a food, a drug, and a feed that each include the composition for promoting sleep. The composition for promoting sleep is characterized in that the composition for promoting sleep includes a microorganism belonging to either Bifidobacterium adolescentis or Lactobacillus plantarum, or a culture thereof as an active ingredient.

Abstract: Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

Abstract: The present invention addresses the problem of providing an effective new means for efficiently reducing the amount of diacylglycerol in a fat/oil (by conversion into triacylglycerol). Disclosed is a method for producing a fat/oil, including a step in which a lipase having a ratio of transesterification activity to hydrolysis activity of 0.007 or higher is caused to act on a diacylglycerol-containing fat/oil.

Abstract: Methods of inhibiting growth of cells or tissue of a primary and/or secondary tumor, and/or of stimulating an immunological response to the tumor, in a subject in need thereof, and systems for performing same, are provided. The methods employ local administration of a gas, such as gaseous nitric oxide, typically at a high dose. Immune cells obtained upon treating a tumor with gaseous nitric oxide, either in vivo or ex vivo, and methods employing same are also provided.

Abstract: The present disclosure provides solutions to various challenges in health, including health challenges related to high consumption of carbohydrate and/or low consumption of soluble fiber. The present disclosure provides, among other things, bacteria engineered for expression of a fiber-synthesizing enzyme, e.g., for expression of the enzyme in the gut (e.g., in the intestine). In particular embodiments, the present disclosure provides bacteria engineered for expression of a fiber-synthesizing enzyme that consumes carbohydrate in the process of synthesizing fiber, e.g., in the gut. The present disclosure further includes formulations of isolated fiber-synthesizing enzymes for administration to subjects.

Abstract: A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.

Abstract: Methods and products for treating capsular contractures of breast implants including (1) platelet-rich fibrin (PRF) fraction from a patient who exhibits capsular contracture of a breast implant; and (2) applying the PRF fraction to said capsular contracture, thereby relaxing the capsular contracture.

Abstract: According to the invention, a novel Bifidobacterial strain having an ability of assimilating two or more kinds of HMO is provided. The strain is selected from the group consisting of Bifidobacterium longum subspecies infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058) and Bifidobacterium bifidum (NITE BP-03067).